NKX101 in acute myeloid leukemia and NKX019 in non-Hodgkin’s lymphoma showed high complete response rates, but without the toxicity associated with CAR-Ts.

As it and its competitors have failed on the first test of durability with their allogeneic CAR-T candidates, Precision Biosciences is looking to cross the line in a sub-group of responders – as well as prove the value of its gene-editing platform.

As big pharma company cash piles grow and biotech share prices plummet, a resurgence in mergers and acquisitions looks imminent.

Novartis hopes a CAR-T with rapid manufacturing will be a winner, while novel bispecific antibodies in lymphoma and myeloma will make appearances, along with next-generation PI3K and BTK inhibitors.